Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2010 (Event Date: June 8, 2010)
Context: Accuray entered into a Strategic Alliance Agreement and a Multiple Linac and Multi-Modality Distribution Agreement with Siemens Aktiengesellschaft ("Siemens").
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes and Agreement Details
- Distribution Rights: Accuray granted Siemens distribution rights to the CyberKnife Robotic Radiosurgery System for inclusion in multi-product sales alongside Siemens' linear accelerator or imaging products. Each sale requires Accuray's pre-approval.
- Global Expansion: The parties agreed to negotiate separate distribution agreements for CyberKnife in countries and regions not currently fully served by Accuray.
- Joint R&D: A Steering Committee will develop a product concept for joint technology development within six months. Accuray will manufacture components ("Accuray Components") for incorporation into Siemens' linear accelerator products ("Cayman Products").
- Compensation: Siemens agreed to pay Accuray an arrangement fee for the first Cayman Product, payable in installments based on milestones. Accuray is obligated to incur development costs exceeding this fee.
- Exclusivity and Termination: Siemens holds exclusive rights to purchase Accuray Components for Cayman Products, subject to termination if sales targets are missed or if initial shipment does not occur within 12 months of FDA 510(k) clearance. The agreement has a five-year initial term with automatic one-year renewals.
Guidance, Outlook, and Risks
- Outlook: The alliance aims to expand global distribution of CyberKnife and share technology. A second Cayman Product is contingent on satisfying specific conditions and milestones.
- Risks and Contingencies:
- Exclusivity rights are conditional on meeting sales targets and regulatory timelines.
- Either party may terminate the agreement in the event of a material breach.
- Either party may terminate supply and distribution rights if the other is acquired by a specified competitor ("Acquisition Change").
- Management Commentary: The company issued a press release on June 9, 2010, announcing the strategic alliance to expand global distribution and share technology.
Investor Verification Checklist
- Verify the specific sales targets required to maintain Siemens' exclusivity on Accuray Components.
- Monitor the timeline for FDA 510(k) clearance of Accuray Components to assess the 12-month shipment deadline.
- Review the full text of the Alliance and Distribution Agreements when filed as exhibits to the Form 10-K for the year ended June 30, 2010.
- Assess the potential financial impact of the arrangement fee and the obligation for Accuray to cover development costs in excess of that fee.
- Track the progress of the Steering Committee's product concept development within the six-month window.